Novel 1,4-benzodiazepine derivatives with antiproliferative properties on tumor cell lines

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 9, 2007, Pages 2527-2530

  Dourlat, Jennifer ^a,b   Liu, Wang Qing ^a,b   Gresh, Nohad ^a,b   Garbay, Christiane ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

Author keywords

1,4 Benzodiazepines; Cancer; Melanoma; Proliferation

Indexed keywords

4' CHLORODIAZEPAM; BENZODIAZEPINE DERIVATIVE;

ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; MELANOMA CELL; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BENZODIAZEPINES; BENZODIAZEPINONES; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INHIBITORY CONCENTRATION 50; MELANOMA; MODELS, CHEMICAL; MOLECULAR CONFORMATION;

EID: 33947714354     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.02.016     Document Type: Article

References (22)

1. Nordenberg J., Fenig E., Landau M., Weizman R., and Weizman A. Biochem. Pharmacol. 58 (1999) 1229
2. Boitano A., Ellman J.A., Glick G.D., and Opipari Jr. A.W. Cancer Res. 63 (2003) 6870
3. Lamb M.L., Burdick K.W., Toba S., Young M.M., Skillman A.G., Zou X., Arnold J.R., and Kuntz I.D. Proteins 42 (2001) 296
4. Yu H., and Jove R. Nat. Rev. Cancer 4 (2004) 97
5. Becker S., Groner B., and Muller C.W. Nature 394 (1998) 145
6. Cao X., Tay A., Guy G.R., and Tan Y.H. Mol. Cell Biol. 16 (1996) 1595
7. Niu G., Bowman T., Huang M., Shivers S., Reintgen D., Daud A., Chang A., Kraker A., Jove R., and Yu H. Oncogene 21 (2002) 7001
8. Hess S., Smola H., Sandaradura De Silva U., Hadaschik D., Kube D., Baldus S.E., Flucke U., and Pfister H. J. Immunol. 165 (2000) 1939
9. Carpino L.A., and El-Faham A. J. Am. Chem. Soc. 117 (1995) 5401
10. Silverberg L.J., Dillon J.L., and Vemishetti P. Tetrahedron Lett. 37 (1996) 771
11. Nishizawa S., Cui Y.Y., Minagawa M., Morita K., Kato Y., Taniguchi S., Kato R., and Teramae N. J. Chem. Soc., Perkin Trans. 2 (2002) 866
12. Baczko K., Liu W.Q., Roques B.P., and Garbay-Jaureguiberry C. Tetrahedron 52 (1996) 2021
13. Nadin A., Lopez J.M., Owens A.P., Howells D.M., Talbot A.C., and Harrison T. J. Org. Chem. 68 (2003) 2844
14. Ramdas L., Bunnin B.A., Plunkett M.J., Sun G., Ellman J., Gallick G., and Budde R.J. Arch. Biochem. Biophys. 368 (1999) 394
15. 50 was determined from a sigmoidal dose-response curve using GraphPad Prism (GraphPad Software, San Diego, CA).
16. 50 was determined from a sigmoidal dose-response curve using GraphPad Prism (GraphPad Software, San Diego, CA).
17. Zisterer D.M., Hance N., Campiani G., Garofalo A., Nacci V., and Williams D.C. Biochem. Pharmacol. 55 (1998) 397
18. Carmel I., Fares F.A., Leschiner S., Scherubl H., Weisinger G., and Gavish M. Biochem. Pharmacol. 58 (1999) 273
19. Camins A., Diez-Fernandez C., Pujadas E., Camarasa J., and Escubedo E. Eur. J. Pharmacol. 272 (1995) 289
20. Mikol V., Baumann G., Keller T.H., Manning U., and Zurini M.G. J. Mol. Biol. 246 (1995) 344
21. Sundberg T.B., Ney G.M., Subramanian C., Opipari Jr. A.W., and Glick G.D. Cancer Res. 66 (2006) 1775
22. Herlyn M., Clark W.H., Rodeck U., Mancianti M.L., and Jambrosic J. Lab. Invest. 56 (1987) 461